Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.62 |
| ▸ | ESR1 | P03372 | 4/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932849 | 1.00 | ESR2 (0.62) | ESR2ESR1PTPN1DRD2DRD4 | |
| SCHEMBL1933740 | 0.78 | ESR1 (0.82) | ESR2ESR1PTPN1DRD2DRD4 | |
| SCHEMBL1932818 | 0.78 | ESR1 (0.82) | ESR2ESR1PTPN1DRD2DRD4 | |
| SCHEMBL1934690 | 0.78 | ESR1 (0.82) | ESR2ESR1PTPN1DRD2DRD4 | |
| Tupichinol C SCHEMBL6822846 | 0.77 | ESR2 (1.00) | ESR2ESR1PTPN1CHRNA7 | |
| Tupichinol C SCHEMBL31060867 | 0.77 | ESR2 (1.00) | ESR2ESR1PTPN1CHRNA7 | |
| Tupichinol C SCHEMBL2960172 | 0.77 | ESR2 (1.00) | ESR2ESR1PTPN1CHRNA7 | |
| Tupichinol C SCHEMBL30205825 | 0.77 | ESR2 (1.00) | ESR2ESR1PTPN1CHRNA7 | |
| SCHEMBL22882746 | 0.77 | ESR2 (0.75) | ESR2ESR1PTPN1DRD2DRD4 | |
| SCHEMBL6499654 | 0.75 | ESR2 (0.68) | ESR2ESR1PTPN1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2504339-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064211-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | CYP1B1, CYP11B2, CCNI | ESR2 290/4885ESR1 561/4885PTPN1 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.